RAJDEEP SARDESAI, one of the most visible faces of Indian news television today, is the Editor-in-Chief of IBN18 Network which includes CNN-IBN, IBN7 and Lokmat. He has made a name for himself in his 22 years of television journalism with his incisive political reporting of events such as the Gujarat carnage of 2002. As a television anchor, he is known for his signature conversational style. Sardesai has also served as...

Justice Markandey Katju's prescription for a regulated media regime is a misplaced step that can actually de-democratise the fourth estate. IT is open season on the political class and the news media. But then, again, it's more like a chase of one's own tail. A self-righteous, delusional, Anna-Baba NGO-ised fringe sets out to stigmatise politics and Members of Parliament; the news media salivate at the prospect and rush to provide...

A report by a parliamentary committee has shown that the drug industry regulator, the Drug Controller General of India (DCGI), has been approving, on average, one new drug a month without conducting mandatory clinical trials or seeking expert medical opinion—findings that expose the deep flaws prevalent in India’s drug approval process. The committee has asked the health ministry to withdraw the discretionary powers given to the Central Drugs Standard Control Organization...

Police investigation of Sanal Edamaraku for debunking a “miracle” at a church is a crime against the Constitution. Early in March, little drops of water began to drip from the feet of the statue of Jesus nailed to the cross on the church of Our Lady of Velankanni, down on to Mumbai's unlovely Irla Road. Hundreds began to flock to the church to collect the holy water in little plastic bottles,...

Fighting cancer has just become less expensive for millions of Indian patients. More than 12 years after he electrified the pharma industry by taking on powerful global giants in his quest to supply cheap anti-AIDS drugs, Cipla promoter YK Hamied is back donning the role of a price warrior. This time, his attention is on anti-cancer drugs. On Thursday, Cipla cut prices of key cancer drugs by nearly 75%, an astounding,...